B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders

Journal of Neuroimmunology

Volumn 204, Issue 1-2, 2008, Pages 1-12

  Stübgen, Joerg Patrick ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Autoimmune polyneuropathy; B cell depletion; Inflammatory myopathy; Myasthenia gravis; Rituximab

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; CD20 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; GANGLIOSIDE ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN M ANTIBODY; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1; MERCAPTOPURINE; METHYLPREDNISOLONE; MYELIN ASSOCIATED GLYCOPROTEIN; PLACEBO; PREDNISOLONE; PREDNISONE; PYRIDOSTIGMINE; RITUXIMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VINCRISTINE;

ANTI SRP SYNDROME; ANTIBODY PRODUCTION; ANTIGEN BINDING; ANTISYNTHETASE SYNDROME; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BRONCHOSPASM; CHILL; CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULOPATHY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPLEMENT ACTIVATION; CRYOGLOBULINEMIA; CYTOTOXICITY; DERMATOMYOSITIS; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG TARGETING; DRUG WITHDRAWAL; FEVER; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOMODULATION; INJECTION SITE REACTION; INNATE IMMUNITY; LOW DRUG DOSE; MONOTHERAPY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MYASTHENIA GRAVIS; MYOSITIS; NEUROMUSCULAR DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PERIPHERAL NEUROPATHY; POLYMYOSITIS; POLYRADICULONEUROPATHY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; RIGOR; SENSORY NEUROPATHY; SJOEGREN SYNDROME; TREATMENT OUTCOME; WALDENSTROEM MACROGLOBULINEMIA;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; HUMANS; IMMUNOLOGIC FACTORS; NEUROMUSCULAR DISEASES;

EID: 54349123783     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.07.019     Document Type: Review

References (156)

1. Alas S., and Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 61 (2001) 5137-5144
2. Alawyn I.P., Xu Y., Basker M., Wu C., Buhler L., Lambrights D., Treter S., Kitamura H., Vitetta E.S., Abraham S., Awwad M., White-Scharf M.E., Sachs D.H., Thall A., and Cooper D.K. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in decreased production of anti-alphaGal antibody. Xenotransplantation 8 (2001) 157-171
3. Arasaki K., Kusunoki S., Kudo N., and Kanazawa I. Acute conduction block in vitro following exposure to antiganglioside sera. Muscle Nerve 16 (1993) 587-593
4. Arlet J.B., Dimitri D., Pagnoux C., Boyer O., Maisonobe T., Authier F.J., Bloch-Queyrat C., Goulvestre C., Heshmati F., Atassi M., Guillevin L., Benveniste O., and Mouthon L. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul. Disord. 16 (2006) 334-336
5. Arkfeld D.G. The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol. Int. 28 (2008) 205-215
6. Ascherman D.P. The role of Jo-1 in the immunopathogenesis of polymyositis. Curr. Rheumatol. Rep. 5 (2003) 425-430
7. Baek W.S., Bashey A., and Sheean G.L. Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis. J. Neurol. Neurosurg. Psychiatry 78 (2007) 771
8. Bar-Or A., Calabresi P., Arnold D., Markowitz C., Shafer S., and Kasper L. A phase I, open-label, multicenter study to evaluate the safety and efficacy of rituximab in adults with relapsing and remitting multiple sclerosis (RRMS). American Academy of Neurology 59th Annual Meeting (2007) Boston, April 28-May 5, [Abstract No. S.02.001]
9. Benedetti L., Briani C., Grandis M., Vigo T., Gobbi M., Ghiglione E., Carpo M., Cocito D., Caporale C.M., Sormani M.P., Mancardi G.L., Nobile-Orazio E., and Schenone A. Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M. J. Peripher. Nerv. Syst. 12 (2007) 102-107
10. Bernasconi N., Traggiai E., and Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298 (2002) 2199-2202
11. Birnbaum G., Antel J., and Hartung H.P. Introduction to immunology. In: Antel J., Birnbaum G., Hartung H.P., and Vincent A. (Eds). Clinical Neuroimmunology (2005), Oxford University Press, New York 1-11
12. Braun A., Neumann T., Oelzner P., Hein G., Grone H.J., Ziemer M., and Wolf G. Cryoglobulinemia type III with severe neuropathy and immune complex glomerulonephritis: remission after plasmapheresis and rituximab. Rheumatol. Int. 28 (2008) 503-506
13. Briani C., Zara G., Zambello R., Trentin L., Rana M., and Zaja F. Rituximab-responsive CIDP. Eur. J. Neurol. 11 (2004) 788
14. Briani C., Doria A., Sarzi-Puttini P., and Dalakas M.C. Update on idiopathic inflammatory myopathies. Autoimmunity 39 (2006) 161-170
15. Broglio L., and Lauria G. Worsening after rituximab treatment in anti-MAG neuropathy. Muscle Nerve 32 (2005) 378-379
16. Brulhart L., Waldburger J.M., and Gabay C. Rituximab in the treatment of antisynthase syndrome. Ann. Rheum. Dis. 65 (2006) 974-975
17. Cai F.Z.J., Ahern M., and Smith M. Treatment of cryoglobulinemia associated peripheral neuropathy with rituximab. J. Rheumatol. 33 (2006) 1197-1198
18. Carpo M., Nobile-Orazio E., Meucci N., Gamba M., Barbieri S., Allaria S., and Scarlato G. Anti-GD1a ganglioside antibodies in peripheral motor syndromes. Ann. Neurol. 39 (1996) 539-543
19. Chad D., Pariser K., Bradley W.G., Adelman L.S., and Pinn V.W. The pathogenesis of cryoglobulinemic neuropathy. Neurology 32 (1982) 725-729
20. Chan O.T., Madaio M.P., and Shlomchik M.J. The central and multiple roles of B cells in lupus pathogenesis. Immunol. Rev. 169 (1999) 107-121
21. Chiappetta N., Steier J., and Gruber B. Rituximab in the treatment of refractory dermatomyositis. J. Clin. Rheumatol. 11 (2005) 264-266
22. Christopher-Stine L., and Plotz P.H. Myositis: an update on pathogenesis. Curr. Opin. Rheumatol. 16 (2004) 700-706
23. Chung L., Genovese M.C., and Fiorentino D.F. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch. Dermatol. 143 (2007) 763-767
24. Clark E.A., and Ledbetter J.A. How does B cell depletion in therapy work, and how can it be improved?. Ann. Rheum. Dis. Suppl. 64 (2005) 77-80
25. Clynes R.A., Towers T.L., Presta L.G., and Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6 (2000) 443-446
26. Cohen S.B. B-cell depletion for rheumatic diseases: where are we. Med. Gen. Med. 7 (2005) 72
27. Cooper M.A., Willingham D.L., Brown D.E., French A.R., Shih F.F., and White A.J. Rituximab for the treatment of juvenile dermatomyositis. Arthritis Rheum. 56 (2007) 3107-3111
28. Corse A.M., Chaudry V., Crawford T.O., Cornblath D.R., Kuncl R.W., and Griffin J.W. Sensory nerve pathology in multifocal motor neuropathy. Ann. Neurol. 39 (1996) 319-325
29. Dalakas M.C. Inhibition of B cell functions: implications for neurology. Neurology 70 (2008) 2252-2260
30. Dalakas M.C., and Engel W.K. Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy. Arch. Neurol. 37 (1980) 637-640
31. Dalakas M.C., and Hohlfeld R. Polymyositis and dermatomyositis. Lancet 362 (2003) 971-982
32. Dalakas M.C., Rakocevic G., Salajegheh K., Dambrosia J., Raju R., and McElroy B. A double-blind, placebo-controlled study of rituximab in patients with anti-MAG antibody-demyelinating polyneuropathy (A-MAG-DP). Ann. Neurol. Suppl. 60 (2006) 91
33. Dellagi K., Dupouey P., Brouet J.C., Billecocq A., Gomez D., Clauvel J.P., and Seligman M. Waldenstrom's macroglobulinemia and peripheral neuropathy: a clinical and immunological study of 25 patients. Blood 62 (1983) 280-285
34. Devauchelle-Pensec V., Pennec Y., Morvan J., Pers J.O., Daridon C., Jousse-Joulin S., Roudaut A., Jamin C., Renaudineau Y., Roué I.Q., Cochener B., Youinou P., and Saraux A. Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 15 (2007) 310-317
35. Dighiero G., Lymberi P., Guilbert B., Ternyck T., and Avrameas S. Natural autoantibodies constitute a substantial part of normal circulating immunoglobulins. Ann. N.Y. Acad. Sci. 475 (1986) 135-145
36. Dimopoulos M.A., Zervas C., Zomas A., Kiamouris C., Viniou N.A., Grigoraki V., Karkantaris C., Mitsouli C., Gika D., Christakis J., and Anagnostopoulos N. Treatment of Waldenstrom's macroglobulinemia with rituximab. J. Clin. Oncol. 20 (2002) 2327-2333
37. Dinh H.V., McCormack C., Hall S., and Prince H.M. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J. Am. Acad. Dermatol. 56 (2007) 148-153
38. Dispenzieri A., and Gorevic P.D. Cryoglobulinemia. Hematol. Oncol. Clin. North America 13 (1999) 1315-1349
39. Edwards J.C., and Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B-lymphocytes. Rheumatology 40 (2001) 205-211
40. Edwards J.C., and Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat. Rev., Immunol. 6 (2006) 394-403
41. Edwards J.C., Cambridge G., and Abrahams V.M. Do self-perpetuating B lymphocytes drive human autoimmune disease. Immunology 97 (1999) 188-196
42. Edwards J.C., Leandro M.J., and Cambridge G. B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum. Dis. Clin. North Am. 30 (2004) 393-403
43. Einfeld D.A., Brown J.P., Valentine M.A., Clark E.A., and Ledbetter J.A. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. 7 (1988) 711-717
44. Endo L.M., Theos A., and Atkinson T.P. Use of rituximab in refractory juvenile dermatomyositis. Arthritis Rheum. Suppl. 52 (2005) 288
45. Evoli A., Tonali P.A., Padua L., Monaco M.L., Scuderi F., Batocchi A.P., Marino M., and Bartoccioni E. Clinical correlates with MuSK antibodies in generalized seronegative myasthenia gravis. Brain 126 (2003) 2304-2311
46. Gajra A., Vajpayee N., and Grethlein S.J. Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma. Am. J. Hematol. 77 (2004) 196-197
47. Gironi M., Saresella M., Ceresa L., Calvo M., Ferrante P., Merli F., and Nemni R. Clinical and immunological worsening in a patient with Waldenstrom's macroglobulinemia and anti-MAG neuropathy after treatment with rituximab. Hematologica Suppl. 91 (2006) ECR17
48. Gono T., Matsuda M., Shimojima Y., Ishii W., Yamamoto K., Morita H., Hashimoto T., Suzuki K., Yuki N., and Ikeda S. Rituximab therapy in chronic inflammatory demyelinating polyradiculoneuropathy with anti-SGPG IgM antibody. J. Clin. Neurosci. 13 (2006) 683-687
49. Gorson K.C., Natarajan N., Ropper A.H., and Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot study. Muscle Nerve 35 (2007) 66-69
50. Grant I.A., Hunder G.G., Homburger H.A., and Dyck P.J. Peripheral neuropathy associated with sicca complex. Neurology 48 (1997) 855-862
51. Griffen J.W., Cornblath D.R., Alexander E., Campbell J., Low P.A., and Bird S. Ataxic sensory neuropathy and dorsal root ganglionitis associated with Sjøgren's syndrome. Ann. Neurol. 27 (1990) 304-315
52. Hain B., Jordan K., Deschauer M., and Zierz S. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve 33 (2006) 575-580
53. Hauser S., Waubant E., Arnold D., Vollmer T., Antel J., and Fox R. A phase II randomized, placebo-controlled, multicenter trial of rituximab in adults with relapsing and remitting multiple sclerosis (RRMS). American Academy of Neurology 59th annual meeting (2007) Boston, April 28-May5, [Abstract No. S.12.003]
54. Heiman-Patterson T., Krupa T., Thompson P., Nobile-Orazio E., Tahmoush A.J., and Shy M.E. Anti-GM1/GD1b M-proteins damage human spinal cord neurons co-cultured with muscle. J. Neurol. Sci. 120 (1993) 38-45
55. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., and Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat. Med. 7 (2001) 365-368
56. Kaji R., Oka N., Tsuji T., Mezaki T., Nishio T., Akiguchi I., and Kimura J. Pathological findings at the site of conduction block in multifocal motor neuropathy. Ann. Neurol. 33 (1993) 152-158
57. Kaji R., Hirota N., Oka N., Kohara N., Watanabe T., Nishio T., and Kimura J. Anti-GM1 antibodies and impaired blood-nerve barrier may interfere with remyelination in multifocal motor neuropathy. Muscle Nerve 17 (1994) 108-110
58. Kao A.H., Lacomis D., Lucas M., Fertig N., and Oddis C.V. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum. 50 (2004) 209-215
59. Kaplan J.G., Rosenberg R., Reinitz E., Buchbinder S., and Schaumburg H.H. Peripheral neuropathy in Sjogren's syndrome. Muscle Nerve 13 (1990) 570-579
60. Kieseier B.C., Kiefer R., Gold R., Hemmer B., Willison H.J., and Hartung H.P. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 30 (2004) 131-154
61. Kilidireas C., Anagnostopoulos A., Karandreas N., Mouselimi L., and Dimopoulos M.A. Rituximab therapy in monoclonal IgM-related neuropathies. Leuk. Lymphoma 47 (2006) 859-864
62. Knecht H., Baumberger M., Tobon A., and Steck A. Sustained remission of CIDP associated with Evans syndrome. Neurology 63 (2004) 730-732
63. Kneitz C., Wilhelm M., and Tony H.P. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunology 206 (2002) 519-527
64. Kohler G., and Milstein C. Continuous cultures of fused cells secreting antibody of defined specificity. Nature 256 (1975) 495-497
65. Kornberg A.J., and Pestronk A. Antibody-associated polyneuropathy syndromes: principles and treatment. Semin. Neurol. 23 (2003) 181-189
66. Lambotte O., Kotb R., Maigne G., Blanc F.X., Goujard C., and Delfraissy J.F. Efficacy of rituximab in refractory polymyositis. J. Rheumatol. 32 (2005) 1369-1370
67. Lamprecht P., Lerin-Lozano C., Merz H., Dennin R.H., Gause A., Voswinkel J., Peters S.O., Gutzeit O., Arit A.C., Solbach W., and Gross W.L. Rituximab induces remission in refractory HCV associated cryoglobulinemic vasculitis. Ann. Rheum. Dis. 62 (2003) 1230-1233
68. Lapointe R., Bellemare-Pelletier A., Housseau F., Thibodeau J., and Hwu P. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res. 63 (2003) 2836-2843
69. Leandro M.J., Edwards J.C., and Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann. Rheum. Dis. 61 (2002) 883-888
70. Leandro M.J., Cooper N., Cambridge G., Ehrenstein M.R., and Edwards J.C. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatology 46 (2007) 29-36
71. Levine T.D. A pilot study of rituximab therapy for refractory dermatomyositis. Arthritis Rheum. Suppl. 46 (2002) 488
72. Levine T.D. Rituximab in the treatment of dermatomyositis. An open-label pilot study. Arthritis Rheum. 52 (2005) 601-607
73. Levine T.D., and Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology 52 (1999) 1701-1704
74. Levine T., Pestronk A., Florence J., Al-Lozi M.T., Lopate G., Miller T., Ramneantu I., Waheed W., Stambuk M., Stone M.J., and Choksi R. Peripheral neuropathies in Waldenstrøm's macroglobulinemia. J. Neurol. Neurosurg. Psychiatry 77 (2006) 224-228
75. Lindstrom J.M. Acetylcholine receptors and myasthenia gravis. Muscle Nerve 23 (2000) 453-477
76. Liyanage Y., Hoch W., Beeson D., and Vincent A. The agrin/muscle-specific kinase pathway: new targets for autoimmune and genetic disorders at the neuromuscular junction. Muscle Nerve 25 (2002) 4-16
77. Looney R.J. B cell-targeted therapy in diseases other than rheumatoid arthritis. J. Rheumatol. Suppl. 32 (2005) 25-28
78. Looney R.J. B cell-targeted therapy for rheumatoid arthritis. Drugs 6 (2006) 625-639
79. Love L.A., Leff R.L., Fraser D.D., Targoff I.N., Dalakas M., Plotz P.H., and Miller F.W. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 70 (1991) 360-374
80. Luke P.P., Scantlebury V.P., Jordan M.L., Vivas C.A., Hakala T.R., Jain A., Somani A., Fedorek S., Randhawa P., and Shapiro R. Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Transplantation 72 (2001) 419-422
81. Maloney D.G., Liles T.M., Czerwinski D.K., Waldichuk C., Rosenberg J., Grillo-Lopez A., and Levy R. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84 (1994) 2457-2466
82. Maloney D.G., Smith B., and Appelbaum F.R. The anti-tumor effect of monoclonal anti-CD20 (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines. Blood Suppl. 88 (1996) 637
83. Maloney D.G., Grillo-Lopez A.J., White C.A., Bodkin D., Schilder R.J., Neidhart J.A., Janakiraman N., Foon K.A., Liles T.M., Dallaire B.K., Wey B.K., Royston I., Davis T., and Levy R. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90 (1997) 2188-2195
84. Maloney D.G., Smith B., and Rose A. Rituximab: mechanism of action and resistance. Semin. Oncol. Suppl. 29 (2002) 2-9
85. Marguerie C., Bunn C.C., Beynon H.L., Bernstein R.M., Hughes J.M., So A.K., and Walport M.J. Polymyositis, pulmonary fibrosis and antibodies to aminoacyl-tRNA synthetase enzyme. Q. J. Med. 77 (1990) 1019-1038
86. Mauermann M.L., Ryan M.L., Moon J.S., and Klein C.J. Case of mononeuritis multiplex onset with rituximab therapy for Waldenstrøm's macroglobulinemia. J. Neurol. Sci. 260 (2007) 240-243
87. McLaughlin P., Grillo-Lopez A., Link B.K., Levy R., Czuczman M.S., Williams M.E., Heyman M.R., Bence-Bruckler I., White C.A., Cabanillas F., Jain V., Ho A.D., Lister J., Wey K., Shen D., and Dallaire B.K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16 (1998) 2825-2833
88. Melendez-Vasquez C., Redford J., Choudhary P.P., Gray I.A., Maitland P., Gregson N.A., Smith K.J., and Hughes R.A. Immunological investigation of chronic inflammatory demyelinating polyradiculoneuropathy. J. Neuroimmunol. 73 (1997) 124-134
89. Mellgren S.J., Conn D.L., Stevens J.C., and Dyck P.J. Peripheral neuropathy in primary Sjøgren's syndrome. Neurology 39 (1989) 390-394
90. Moll J.W., Markusse H.M., Pijnenburg J.J., Vecht C.J., and Henzen-Logmans S.C. Antineuronal antibodies in patients with neurologic complications of primary Sjøgren's syndrome. Neurology 43 (1993) 2574-2581
91. Monaco S., Bonetti B., Ferrari S., Moretto G., Nardelli E., Tedesco F., Mollnes T.E., Nobile-Orazio E., Manfredini E., and Bonazzi L. Complement-mediated demyelination in patients with IgM monoclonal gammopathy and polyneuropathy. N. Engl. J. Med. 322 (1990) 649-652
92. Münch C., Anagnostou P., Meyer R., and Haas J. Rituximab in chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus. J. Neurol. Sci. 256 (2007) 100-102
93. Nadler L.M., Ritz J., Hardy R., Pesando J.M., Schlossman S.F., and Stashenko P. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J. Clin. Invest. 67 (1981) 134
94. Newsom-Davis J. The emerging diversity of neuromuscular junction disorders. Acta Myol. 26 (2007) 5-10
95. Ng C.M., Bruno R., Combs D., and Davies B. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J. Clin. Pharmacol. 45 (2005) 792-801
96. Nobile-Orazio E. Neuropathies associated with anti-MAG antibodies and IgM monoclonal gammopathies. In: Latov N., Wokke J.H.J., and Kelly J.J. (Eds). Immunological and infectious diseases of the peripheral nerves (1998), Cambridge University Press, Cambridge 168-189
97. Nobile-Orazio E. Multifocal motor neuropathy. J. Neuroimmunol. 115 (2001) 4-18
98. Nobile-Orazio E., Meucci N., Baldinin L., Di Troia A., and Scarlato G. Long-term prognosis of neuropathy associated with ant-MAG IgM M-proteins and its relationship to immune therapies. Brain 123 (2000) 710-717
99. Nobile-Orazio E., Cappellari A., and Priori A. Multifocal motor neuropathy: current concepts and controversies. Muscle Nerve 31 (2005) 663-680
100. Noronha V., Fynan T.M., and Duffy T. Flare in neuropathy following rituximab therapy for Waldenstrom's macroglobulinemia. J. Clin. Oncol. 24 (2006) e3
101. Noss E.H., Hausner-Sypek D.L., and Weinblatt M.E. Rituximab as therapy for refractory polymyositis and dermatomyositis. J. Rheumatol. 33 (2006) 1021-1026
102. Oh S.J., Claussen G.C., Odabasi Z., and Palmer C.P. Multifocal demyelinating motor neuropathy: pathologic evidence of "inflammatory demyelinating polyradiculoneuropathy. Neurology 45 (1995) 1828-1832
103. Owen R.G., Treon S.P., Al-Katib A., Fonseca R., Greipp P.R., McMaster M.L., Morra E., San Miguel J.F., Branagan A.R., and Dimopoulos M.A. Clinico-pathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macrogloblinemia. Semin. Oncol. 30 (2003) 110-115
104. Pedrazzini A., Freedman A.S., Andersen J., Heflin L., Anderson K., Takvorian T., Canellos G.P., Whitman J., Coral F., and Ritz J. Anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation for B-cell non-Hodgkin's lymphoma: phenotypic reconstitution and B-cell function. Blood 74 (1989) 2203-2211
105. Pescovitz M.D. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am. J. Transplant. 33 (2006) 859-866
106. Pestronk A., Florence J., Miller T., Choksi R., Al-Lozi M.T., and Levine T.D. Treatment of IgM antibody associated polyneuropathies using rituximab. J. Neurol. Neurosurg. Psychiatry 74 (2003) 485-489
107. Quartier P., Brethon B., Philippet P., Landman-Parker J., LeDeist F., and Fischer A. Treatment of childhood autoimmune haemolytic anemia with rituximab. Lancet 358 (2001) 1511-1513
108. Raju R., Shi W., and Dalakas M. The clinical response of rituximab in patients with anti-MAG antibody-demyelinating polyneuropathy (A-MAG-DP) is associated with alteration of lymphocyte homing and induction of regulatory T cells. Ann. Neurol. Suppl. 60 (2006) 95
109. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., Newman R.A., Hanna N., and Anderson D.R. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 (1994) 435-445
110. Renaud S., Gregor M., Fuhr P., Lorenz D., Deutshl G., Gratwohl A., and Steck A.J. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 27 (2003) 611-615
111. Renaud S., Fuhr P., Gregor M., Schweikert K., Lorenz D., Daniels C., Deutschl G., Gratwohl A., and Steck A.J. High-dose rituximab and anti-MAG-associated polyneuropathy. Neurology 66 (2006) 742-744
112. Rivera A., Chen C.C., Ron N., Dougherty J.P., and Ron Y. Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations. Int. Immunol. 13 (2001) 1583-1593
113. Roberts M., Willison H.J., Vincent A., and Newsom-Davis J. Multifocal motor neuropathy human sera block distal motor nerve conduction in mice. Ann. Neurol. 38 (1995) 111-118
114. Rojas-Garcia R., Gallardo E., de Andrés I., De Luna N., Juarez C., Sånchez P., and Illa I. Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab. Neurology 6 (2003) 1814-1816
115. Roskos L.K., Davis C.G., and Schwab G.M. The clinical pharmacology of therapeutic monoclonal antibodies. Drug Dev. Res. 61 (2004) 108-120
116. Rubinstein E., Arkfeld D.G., Metyas S., Shinada S., Ehresmann S., and Liebman H.A. Rituximab treatment for resistant antiphospholipid syndrome. J. Rheumatol. 33 (2006) 355-357
117. Rüegg S.J., Fuhr P., and Steck A.J. Rituximab stabilizes multifocal neuropathy increasingly less responsive to IVIg. Neurology 63 (2004) 2178-2179
118. Sabahi R., and Anolik J.H. B-cell-targeted therapy for systemic lupus erythematosus. Drugs 66 (2006) 1933-1945
119. Sansonno D., De Re V., Lauletta G., Tucci F.A., Boiocchi M., and Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferona with an anti-CD20. Blood 101 (2003) 3818-3826
120. Satake M., Yoshimura T., Iwaki T., Yamada T., and Kobayashi T. Anti-dorsal root ganglion neuron antibody in a case of dorsal root ganglionitis associated with Sjøgren's syndrome. J. Neurol. Sci. 132 (1995) 122-125
121. Seror R., Sordet C., Guillevin L., Hachulla E., Masson C., Ittah M., Candon S., Le Guern V., Aouba A., Sibilia J., Gottenberg J.E., and Mariette X. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjøgren's syndrome. Ann. Rheum. Dis. 66 (2007) 351-357
122. Séve P., Gachon E., Petiot P., Stankovic K., Charhon A., and Broussolle C. Successful treatment with rituximab in a patient with mental nerve neuropathy in primary Sjøgren's syndrome. Rheumatol. Int. 28 (2007) 175-177
123. Sfikakis P.P., Boletis J.N., Lionaki S., Viglkis V., Fragiadaki K.G., Iniotaki A., and Moutsopoulos H.M. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 52 (2005) 501-513
124. Siddiqui K., Cahalane E., Keogan M., and Hardiman O. Chronic ataxic neuropathy with cold agglutinins: atypical phenotype and response to anti-CD20 antibodies. Neurology 61 (2003) 1307-1308
125. Silverman G.J., and Weisman S. Rituximab therapy and immune disorders. Prospects for anti-B cell therapy. Arthritis Rheum. 48 (2003) 1484-1492
126. Specks U., Fervenza F.C., McDonald T.J., and Hogan M.C. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum. 44 (2001) 2836-2840
127. Stasi R., Pagano A., Stipa E., and Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98 (2001) 952-957
128. Steck A.J., Stalder A.K., and Renaud. Anti-myelin-associated glycoprotein neuropathy. Curr. Opin. Neurol. 19 (2006) 458-463
129. Stone M.J., Merlini G., and Pascual V. Autoantibody activity in Waldenstrom's macroglobulinemia. Clin. Lymphoma 5 (2005) 225-229
130. Takagi K., Yoshida A., Iwasaki H., Inoue H., and Ueda T. Anti-CD20 antibody (rituximab) therapy in a myasthenia gravis patient with follicular lymphoma. Ann. Hematol. 84 (2005) 548-550
131. + currents in rat single myelinated nerve fibers. Intern. Med. 39 (2000) 123-127
132. Targoff I.N., Johnson A.E., and Miller F.W. Antibody to signal recognition particle in polymyositis. Arthritis Rheum. 33 (1990) 1361-1370
133. Tatum A.H. Experimental paraprotein neuropathy: demyelination by passive transfer of human anti-myelin-associated glycoprotein. Ann. Neurol. 33 (1993) 502-506
134. Taylor B.V., Wright R.A., Harper C.M., and Dyck P.J. Natural history of 46 patients with multifocal motor neuropathy with conduction block. Muscle Nerve 23 (2000) 900-908
135. Tedder T.F., and Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol. Today 15 (1994) 450-454
136. Tedder T.F., Streuli M., Schlossman S.F., and Saito H. Isolation and structure of cDNA encoding B1 (CD20) cell-surface antigen of human B lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 208-211
137. Thakre M., Inshasi J., and Marashi M. Rituximab in refractory MuSK antibody myasthenia gravis. J. Neurol. 254 (2007) 968-969
138. Thomas F.P., Trojaborg W., Nagy C., Sadiq S.A., Latov N., and Hays A.P. Experimental autoimmune neuropathy with anti-GM1 antibodies and immunoglobulin deposits at the nodes of Ranvier. Acta Neuropathol. 82 (1991) 378-383
139. Thomas F.A., Lovelace R.E., Ding X.S., Sadiq S.A., Petty G.W., Sherman W.H., Latov N., and Hays A.P. Vasculitic neuropathy in a patient with cryoglobulinemia and anti-MAG IgM monoclonal gammopathy. Muscle Nerve 15 (1992) 891-898
140. Tobinai K., Kobayashi Y., Narabayashi M., Ogura M., Kagami Y., Morishima Y., Ohtsu T., Igarashi T., Sasaki Y., Kinoshita T., and Murate T. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. Ann. Oncol. 9 (1998) 527-534
141. Toyka K.V., and Hartung H.P. Chronic inflammatory polyneuritis and neuropathies. Curr. Opin. Neurol. 9 (1996) 240-250
142. Trappe R., Loew A., Thuss-Patience P., Dorken B., and Riess H. Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab-monitoring of antiphospholipid and anti-GP antibodies: a case report. Ann. Hematol. 85 (2006) 134-135
143. Treon S.P., Shima J., and Raje N. Interferong induces CD20 expression in multiple myeloma cells via induction of Pu1 and augments rituximab binding to myeloma cells. Blood Suppl. 94 (2000) 119a
144. Treon S.P., Branagan A.R., Hunter Z., Santos D., Tournhilac O., and Anderson K.C. Paradoxical increase in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann. Oncol. 15 (2004) 1481-1483
145. Vieira C.A., Agarwal A., Book B.K., Sidner R.A., Bearden C.M., Gebel H.M., Roggero A.L., Fineberg N.S., Taber T., Kraus M.A., and Pescovitz M.D. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 77 (2004) 542-548
146. Vigna-Perez M., Hernandez-Castro B., Paredes-Saharopulos O., Portales-Pérez D., Baranda L., Abud-Mendoza C., and Gonzalez-Amaro R. Clinical and immunologic effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res. Ther. 8 (2006) R83
147. Vincent A., Bowen J., Newsom-Davis J., and McConville J. Seronegative generalized myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol. 2 (2003) 99-106
148. Weide R., Heymanns J., and Koppler H. The polyneuropathy associated with Waldenstrom's macroglobulinemia can be treated effectively with chemotherapy and anti-CD20 monoclonal antibody. Br. J. Haematol. 109 (2000) 838-841
149. Willison H.J., and Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 125 (2002) 2591-2625
150. Willison H.J., Paterson G., Veitch J., Inglis G., and Barnett S.C. Peripheral neuropathy associated with monoclonal IgM anti-Pr2 cold agglutinins. J. Neurol. Neurosurg. Psychiatry 56 (1993) 1178-1184
151. Wylam M.E., Anderson P.M., and Kuntz N.L.V. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. J. Pediatr. 143 (2003) 674-677
152. Yan L., and Zhu Z. Development of antibody-based therapeutics for oncology indications. Drug Dev. Res. 67 (2006) 699-728
153. Yan W.X., Taylor J., Andrias-Kauba S., and Pollard J.D. Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann. Neurol. 47 (2000) 765-775
154. Ytterberg S.R. Treatment of refractory polymyositis and dermatomyositis. Curr. Rheumatol. Rep. 8 (2006) 167-173
155. Zaja F., Russo D., Fuga G., Perella G., and Baccarani M. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 55 (2000) 1062-1063
156. Zaja F., De Vita S., Mazzaro C., Sacco S., Damiani D., De Marchi G., Michelutti A., Baccarani M., Fanin R., and Ferraccioli G. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101 (2003) 3827-3834